UK biopharmaceuticals research projects win £4m of funding

Aim to strengthen UK’s position in the sector

A package of projects, studentships and training announced today (13 June) aims to develop research to underpin the production and processing of new types of medicines based on biological molecules in the UK.

These projects will provide the foundations for the UK pharmaceutical sector to strengthen its position in the biopharmaceutical sector to the benefit of society and the economy.

The Bioprocessing Research Industry Club (BRIC), a Biotechnology and Biological Sciences Research Council (BBSRC)-led public-private partnership with the Engineering and Physical Sciences Research Council (EPSRC) and a consortium of 16 industrial partners, including companies such as Pfizer, GlaxoSmithKline, Lonza and Biodesign, is providing £4m to fund the projects.

This money will go to six research projects, eight PhD studentships and a Skills Development School for early stage researchers.

The projects will address current challenges in bioprocessing, while the PhD studentships and Skills Development School will ensure that the next generation of researchers have the technical knowledge and personal skills to secure future UK success in producing biopharmaceuticals.

Each PhD student will spend six months or a year on placement with a partner company where they will develop an understanding of the challenges involved in producing biological medicines on a commercial scale.

Biopharmaceuticals such as vaccines, monoclonal antibodies, hormones and peptide therapeutics, make up over a third of the medicines currently under development and the number of licensed biological medicines is expected to grow by 20% a year.

You may also like

Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part I)

Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth
Research & Development

Hamilton Health Sciences chosen for BirchBioMed burn scar treatment trial

BirchBioMed announces Hamilton Health Sciences’ (HHS) Centre for Burn Research in Ontario as the first contracted clinical trial site for its Phase II/III randomised study of the naturally based compound: FS2.
Research & Development

Indena and TCG GreenChem join forces to advance next-generation ADC technologies

Indena and TCG GreenChem are pleased to announce a new strategic collaboration aimed at accelerating the development of innovative and market-ready payload-linkers: the key component of antibody-drug conjugates (ADCs)
Packaging

SGD Pharma acquires Alphial Srl in a strategic step forward

SGD Pharma is pleased to announce an agreement with Italian Private Equity firm Entangled Capital to acquire Alphial Srl, a leading producer of tubular vials and ampoules headquartered in Italy
Subscribe now